Genetic variation in CYP2D6 impacts neural activation during cognitive tasks in humans

NeuroImage

Volumn 59, Issue 3, 2012, Pages 2818-2823

  Stingl, Julia C ^a   Esslinger, Christine ^b   Tost, Heike ^b   Bilek, Edda ^b   Kirsch, Peter ^b   Ohmle, Barbara ^a   Viviani, Roberto ^a   Walter, Henrik ^c   Rietschel, Marcella ^b   Meyer Lindenberg, Andreas ^b  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

CYP2D6; Cytochrome P450; Emotional face watching task; FMRI; Functional imaging; Neurocognition; Polymorphism; Working memory

Indexed keywords

CYTOCHROME P450 2D6;

ADULT; AGE DISTRIBUTION; ALERTNESS; ALLELE; ARTICLE; BOLD SIGNAL; BRAIN FUNCTION; CENTRAL NERVOUS SYSTEM; COGNITION; CONTROLLED STUDY; CUNEUS; ENZYME ACTIVITY; ENZYME ANALYSIS; FACIAL EXPRESSION; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUSIFORM GYRUS; GENE DUPLICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; IMAGE PROCESSING; IMPLICIT MEMORY; MALE; NORMAL HUMAN; PATTERN RECOGNITION; PRECUNEUS; PRIORITY JOURNAL; SEX DIFFERENCE; TASK PERFORMANCE; THALAMUS; WORKING MEMORY;

ADULT; ALLELES; BRAIN MAPPING; COGNITION; CYTOCHROME P-450 CYP2D6; EMOTIONS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MEMORY, SHORT-TERM; OXYGEN; POLYMERASE CHAIN REACTION; PSYCHOMOTOR PERFORMANCE; SOCIAL PERCEPTION;

EID: 84855462649     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2011.07.052     Document Type: Article

References (47)

1. Bertilsson L., Alm C., De Las Carreras C., Widen J., Edman G., Schalling D. Debrisoquine hydroxylation polymorphism and personality. Lancet 1989, 1(8637):555.
2. Callicott J.H., Bertolino A., Mattay V.S., Langheim F.J., Duyn J., Coppola R., et al. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb. Cortex 2000, 10(11):1078-1092.
3. Deng Y., Newman B., Dunne M.P., Silburn P.A., Mellick G.D. Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease. Ann. Neurol. 2004, 55(6):897.
4. Dutheil F., Beaune P., Loriot M.A. Xenobiotic metabolizing enzymes in the central nervous system: contribution of cytochrome P450 enzymes in normal and pathological human brain. Biochimie 2008, 90(3):426-436.
5. Dutheil F., Jacob A., Dauchy S., Beaune P., Scherrmann J.M., Decleves X., et al. ABC transporters and cytochromes P450 in the human central nervous system: influence on brain pharmacokinetics and contribution to neurodegenerative disorders. Expert Opin. Drug Metab. Toxicol. 2011, 6(10):1161-1174.
6. Elbaz A., Levecque C., Clavel J., Vidal J.S., Richard F., Amouyel P., et al. CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease. Ann. Neurol. 2004, 55(3):430-434.
7. Esslinger C., Walter H., Kirsch P., Erk S., Schnell K., Arnold C., et al. Neural mechanisms of a genome-wide supported psychosis variant. Science 2009, 324(5927):605.
8. Fichna J., Janecka A., Costentin J., Do Rego J.C. The endomorphin system and its evolving neurophysiological role. Pharmacol. Rev. 2007, 59(1):88-123.
9. Friedman L., Glover G.H. Report on a multicenter fMRI quality assurance protocol. J. Magn. Reson. Imaging 2006, 23(6):827-839.
10. Gaedigk A., Simon S.D., Pearce R.E., Bradford L.D., Kennedy M.J., Leeder J.S. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 2008, 83(2):234-242.
11. Gasso P., Mas S., Alvarez S., Trias G., Bioque M., Oliveira C., et al. Xenobiotic metabolizing and transporter genes: gene-gene interactions in schizophrenia and related disorders. Pharmacogenomics 2010, 11(12):1725-1731.
12. Gonzalez I., Penas-Lledo E.M., Perez B., Dorado P., Alvarez M., LLerena A. Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers. Pharmacogenomics 2008, 9(7):833-840.
13. Groot A.S., de Sonneville L.M., Stins J.F., Boomsma D.I. Familial influences on sustained attention and inhibition in preschoolers. J. Child Psychol. Psychiatry 2004, 45(2):306-314.
14. Hariri A.R., Bookheimer S.Y., Mazziotta J.C. Modulating emotional responses: effects of a neocortical network on the limbic system. NeuroReport 2000, 11(1):43-48.
15. Hiroi T., Imaoka S., Funae Y. Dopamine formation from tyramine by CYP2D6. Biochem. Biophys. Res. Commun. 1998, 249(3):838-843.
16. Kirchheiner J., Nickchen K., Bauer M., Wong M.L., Licinio J., Roots I., et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 2004, 9(5):442-473.
17. Kirchheiner J., Seeringer A., Godoy A.L., Ohmle B., Maier C., Beschoner P., et al. CYP2D6 in the brain: genotype effects on resting brain perfusion. Mol. Psychiatry 2010, 16(3). 237, 333-341.
18. Llerena A., Edman G., Cobaleda J., Benitez J., Schalling D., Bertilsson L. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr. Scand. 1993, 87(1):23-28.
19. Mann A., Miksys S., Lee A., Mash D.C., Tyndale R.F. Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment. Neuropharmacology 2008, 55(7):1147-1155.
20. Mann A., Tyndale R.F. Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells. Eur. J. Neurosci. 2011, 31(7):1185-1193.
21. McCann S.J., Pond S.M., James K.M., Le Couteur D.G. The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis. J. Neurol. Sci. 1997, 153(1):50-53.
22. Meyer-Lindenberg A., Weinberger D.R. Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat. Rev. Neurosci. 2006, 7(10):818-827.
23. Miksys S., Rao Y., Hoffmann E., Mash D.C., Tyndale R.F. Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. J. Neurochem. 2002, 82(6):1376-1387.
24. Miksys S.L., Tyndale R.F. Drug-metabolizing cytochrome P450s in the brain. J. Psychiatry Neurosci. 2002, 27(6):406-415.
25. Nichols T., Brett M., Andersson J., Wager T., Poline J.B. Valid conjunction inference with the minimum statistic. NeuroImage 2005, 25(3):653-660.
26. Parasumaran R. Consistency of individual differences in human vigilance performance: an abilities classificaton analysis. J. Appl. Psychol. 1976, 61:486-492.
27. Paus T. Functional anatomy of arousal and attention systems in the human brain. Prog. Brain Res. 2000, 126:65-77.
28. Paus T., Zatorre R., Hofle N., Caramanos Z., Gotman J., Petrides M., et al. Time-related changes in neural systems underlying attention and arousal during the performance of an auditory vigilance task. J. Cogn. Neurosci. 1997, 9(3):392-408.
29. Penas-Lledo E.M., Dorado P., Aguera Z., Gratacos M., Estivill X., Fernandez-Aranda F., et al. High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders. Mol. Psychiatry 2011, 16(7):691-692.
30. Penas-Lledo E.M., Dorado P., Pacheco R., Gonzalez I., Llerena A. Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers. Pharmacogenomics 2009, 10(7):1111-1120.
31. Polderman T.J., Posthuma D., De Sonneville L.M., Stins J.F., Verhulst F.C., Boomsma D.I. Genetic analyses of the stability of executive functioning during childhood. Biol. Psychol. 2007, 76(1-2):11-20.
32. Posner M., Raichle M.E. Images of the Mind. New York 1994.
33. Price C.J., Moore C.J., Friston K.J. Subtractions, conjunctions, and interactions in experimental design of activation studies. Hum. Brain Mapp. 1997, 5(4):264-272.
34. Raichle M.E., Fiez J.A., Videen T.O., MacLeod A.M., Pardo J.V., Fox P.T., et al. Practice-related changes in human brain functional anatomy during nonmotor learning. Cereb. Cortex 1994, 4(1):8-26.
35. Ramaekers J.G., Muntjewerff N.D., O'Hanlon J.F. A comparative study of acute and subchronic effects of dothiepin, fluoxetine and placebo on psychomotor and actual driving performance. Br. J. Clin. Pharmacol. 1995, 39(4):397-404.
36. Schmitt J.A., Ramaekers J.G., Kruizinga M.J., van Boxtel M.P., Vuurman E.F., Riedel W.J. Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man. J. Psychopharmacol. 2002, 16(3):207-214.
37. Schmitt J.A., Wingen M., Ramaekers J.G., Evers E.A., Riedel W.J. Serotonin and human cognitive performance. Curr. Pharm. Des. 2006, 12(20):2473-2486.
38. Shen H.W., Jiang X.L., Yu A.M. Nonlinear pharmacokinetics of 5-methoxy-N, N-dimethyltryptamine in mice. Drug Metab. Dispos. 2011, 39(7):1227-1234.
39. Siegle I., Fritz P., Eckhardt K., Zanger U.M., Eichelbaum M. Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 2001, 11(3):237-245.
40. Sridar C., Snider N.T., Hollenberg P.F. Anandamide oxidation by wild type and polymorphically expressed CYP2B6 and CYP2D6. Drug Metab. Dispos. 2011, 39(5):782-788.
41. Stingl J.C., Viviani R. CYP2D6 in the brain: impact on suicidality. Clin. Pharmacol. Ther. 2011, 89(3):352-353.
42. Traskman L., Asberg M., Bertilsson L., Sjostrand L. Monoamine metabolites in CSF and suicidal behavior. Arch. Gen. Psychiatry 1981, 38(6):631-636.
43. Wingen M., Kuypers K.P., van de Ven V., Formisano E., Ramaekers J.G. Sustained attention and serotonin: a pharmaco-fMRI study. Hum. Psychopharmacol. 2008, 23(3):221-230.
44. Worsley K.J., Marrett S., Neelin P., Vandal A.C., Friston K.J., Evans A.C. A unified statistical approach for determining significant signals in images of cerebral activation. Hum. Brain Mapp. 1996, 4(1):58-73.
45. Yu A.M., Idle J.R., Byrd L.G., Krausz K.W., Kupfer A., Gonzalez F.J. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 2003, 13(3):173-181.
46. Zackrisson A.L., Lindblom B., Ahlner J. High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases. Clin. Pharmacol. Ther. 2010, 88(3):354-359.
47. Zhu W. CYP2D6: a key enzyme in morphine synthesis in animals. Med. Sci. Monit. 2008, 14(11):SC15-SC18.